Kopran Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹234Cr
- +35.8% YoY
- +20.5% QoQ
- Net profit
- ₹19Cr
- +94.9% YoY
- +102% QoQ
- Margin
- 14.08%
- +4.2 pp YoY
- +4.9 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q4 FY26 key numbers
- Revenue
- Total Revenue FY 2025-26: Rs. 68,142 Lakhs (no prior year FY revenue for direct comparison on this page).
As stated in Kopran Ltd's Q4 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs. EBITDA for Q4 FY 2025-26: Rs. 4,057 Lakhs; up from Rs. 1,400 Lakhs in Q4 FY 2024-25 (almost 190% increase).
From Kopran Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs
- Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs
- Year-on-year revenue growth (Q4 FY 2025-26 vs Q4 FY 2024-25): Rs. 6,166 Lakhs increase (~35.8% growth)
2 more points from Kopran Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus on R&D to develop niche, high-value/high-volume APIs and intermediates (Page 15).
- Capacity expansion planned as a strategic imperative (Page 15).
- API and R&D facility located at Panoli (Gujarat) indicated as part of capacity expansion (Page 15).
2 more points from Kopran Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Kopran Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 234 | 172 | +35.8% | 194 | +20.5% |
| Operating profit (EBITDA) | 33 | 17 | +92.7% | 18 | +85.5% |
| Operating margin | 14.08% | 9.92% | +4.2 pp | 9.14% | +4.9 pp |
| Profit before tax | 25 | 14 | +84.8% | 11 | +135.9% |
| Net profit (PAT) | 19 | 10 | +94.9% | 9 | +102% |
| EPS (₹) | 3.91 | 2.01 | +94.5% | 1.94 | +101.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q4 FY26 results?
Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs. EBITDA for Q4 FY 2025-26: Rs. 4,057 Lakhs; up from Rs. 1,400 Lakhs in Q4 FY 2024-25 (almost 190% increase).
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on R&D to develop niche, high-value/high-volume APIs and intermediates (Page 15). - Capacity expansion planned as a strategic imperative (Page 15). - API and R&D facility located at Panoli (Gujarat) indicated as part of capacity expansion (Page 15). - Manufacturing facilities with global accreditations at existing locations in Maharashtra: API vertical at MIDC Mahad (11,900 sq.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
